Dey company profile

Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. The US leader in sales of nebulized respiratory medications, DEY® was founded in 1978 and is based in Napa, California.

DEY® PRODUCTS

Since 1999, DEY® has introduced and/or marketed a number of branded products, complementing the company’s traditional strengths in providing high-quality generic drug products. These patent-protected products account for the majority of total company sales.

• AccuNeb® (albuterol sulfate) Inhalation Solution
• Curosurf® (poractant alpha) Intratracheal Suspension
  o DEY® markets and distributes Curosurf® Intratracheal Suspension in the United States for Chiesi Farmaceutici, Parma, Italy.
• Cyanokit® (hydroxocobalamin for injection)
• EpiPen® (epinephrine) Auto-Injector
  o DEY® markets and distributes EpiPen® Auto-Injector for King Pharmaceuticals.
• ZYFLO CR™ (zileuton) extended release tablets
  o Upon product launch, DEY® will co-market twice daily ZYFLO CR™ Tablets through a strategic partnership with Critical Therapeutics, Inc (CRTX).
  
• ZYFLO® (zileuton tablets)
  o DEY® co-markets Zyflo® through a strategic partnership with Critical Therapeutics, Inc (CRTX).
• Perforomist™ (formoterol fumarate) Inhalation Solution
  o Upon product launch by DEY®, CRTX will co-promote Perforomist™ Inhalation Solution.
  

IMPORTANT SAFETY INFORMATION FOR PERFOROMIST™

There is an increased risk of asthma-related death with long-acting beta2-agonists, the class of drugs to which PERFOROMISTTM Inhalation Solution belongs. PERFOROMISTTM Inhalation Solution is not indicated for asthma or in deteriorating COPD. PERFOROMISTTM Inhalation Solution should not be used to treat acute symptoms, which should be treated with an inhaled short-acting beta2-agonist.

Please see Brief Summary, including Boxed Warning on the adjacent page.

PRODUCT DEVELOPMENT AND EXPANSION

For the future, DEY® will continue to expand its product line of patented, branded products. Our Pharmaceutical Development scientists work at the forefront of unit-dose oral inhalation technology to develop new products for respiratory conditions. We are currently working on intranasal technology in an effort to provide a uniform dose of active ingredient every time a nasal spray pump is actuated. DEY® is also taking steps to broaden its product portfolio with the development of other drug delivery systems. At all times, DEY® works not only to meet, but to exceed, regulatory requirements.

GROWTH

DEY® has grown rapidly in the past decade. Annual net sales and the employee base have tripled since 1993. The company's manufacturing facilities in Napa have been enlarged from 30,000 square feet to more than 300,000 square feet.

Media contacts: Dey, L.P. Media Line
1-800-755-5560 ext. 8363

Or

Harriet Ullman hullman@fkhealth.com
Feinstein Kean Healthcare
617-761-6776
DEY® is a registered trademark of Dey, L.P.